Research map: Efficacy and safety of surufatinib plus PD-1/PD-L1 inhibitors as first-line maintenance therapy in extensive-stage small cell lung cancer

Back to the article

Papers in this map

  1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries · Freddie Bray · 2024 · 26051 citations · Cited by this paper
  2. Advances in biomimetic nanomaterials for targeted drug delivery in colon cancer · 2026 · Related
  3. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer · Leora Horn · 2018 · 3642 citations · Cited by this paper
  4. Cell-based and cell-derived strategies for anticancer therapy-related renal injury: progress, challenges, and translational perspectives · 2026 · Related
  5. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial · Luis G Paz-Ares · 2019 · 2314 citations · Cited by this paper
  6. Characteristics and survival associated with pathological complete response following neoadjuvant treatment of locally advanced gastric cancer: a multicenter analysis in a real-world setting · 2026 · Related
  7. Cancer incidence and mortality in China, 2022 · Bingfeng Han · 2024 · 2241 citations · Cited by this paper
  8. Clinical trial design in rare mutation tumors · 2025 · Related
  9. Small-cell lung cancer · Charles M. Rudin · 2021 · 1631 citations · Cited by this paper
  10. Current situation and unmet demands of supportive care for cancer patients in China · 2026 · Related
  11. Small-cell lung cancer: what we know, what we need to know and the path forward · Adi F. Gazdar · 2017 · 950 citations · Cited by this paper
  12. Review of radiotherapy combined with immune checkpoint inhibitors for microsatellite stable locally advanced rectal cancer · 2026 · Related
  13. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity · Won Suk Lee · 2020 · 704 citations · Cited by this paper
  14. Effects of resistance exercise and compression garments in the management of breast cancer-related lymphedema: a randomized controlled trial · 2026 · Related
  15. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ · Anne‐Marie C. Dingemans · 2021 · 626 citations · Cited by this paper
  16. Combination of approved chemotherapeutics and natural products for topoisomerase II targeting: efficacy and safety in cancer therapy · 2025 · Related
  17. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? · Kristy J. Gotink · 2009 · 499 citations · Cited by this paper
  18. Substitution mutational signatures across pan-squamous cell carcinomas · 2026 · Related
  19. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial · Jie Wang · 2022 · 435 citations · Cited by this paper
  20. Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC) · Shirish M. Gadgeel · 2018 · 225 citations · Cited by this paper
  21. Small Cell Lung Cancer · So Yeon Kim · 2025 · 196 citations · Cited by this paper
  22. Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC) · Andreas Nicholas Saltos · 2020 · 174 citations · Cited by this paper
  23. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial · Ying Cheng · 2024 · 162 citations · Cited by this paper
  24. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial · Ying Cheng · 2024 · 138 citations · Cited by this paper
  25. Signal pathways and precision therapy of small-cell lung cancer · Min Yuan · 2022 · 137 citations · Cited by this paper
  26. Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer · Ying Cheng · 2024 · 68 citations · Cited by this paper
  27. Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective · Negar Sadat Sherafat · 2025 · 60 citations · Cited by this paper
  28. Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of 358 patients · Li‐Ling Huang · 2021 · 50 citations · Cited by this paper
  29. Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer · Guanghui Gao · 2022 · 26 citations · Cited by this paper
  30. Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration · Guanghui Gao · 2022 · 20 citations · Cited by this paper
  31. Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors · Brett H. Herzog · 2022 · 16 citations · Cited by this paper
  32. [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition)]. · 2024 · 12 citations · Cited by this paper
  33. A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer · Gabriela Galffy · 2023 · 9 citations · Cited by this paper
  34. Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial · Changgong Zhang · 2024 · 8 citations · Cited by this paper
  35. Abstract 4187: Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF1R kinases · Jinghong Zhou · 2017 · 6 citations · Cited by this paper
  36. FP14.08 Cabozantinib Plus Atezolizumab in NSCLC Patients Previously Treated with a Checkpoint Inhibitor: Results from COSMIC 021 · Joel W. Neal · 2021 · 6 citations · Cited by this paper
  37. Efficacy and safety of surufatinib in the treatment of advanced solid tumors: a systematic evaluation and meta‑analysis · Tianying Cai · 2023 · 6 citations · Cited by this paper
  38. Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial · Ying Cheng · 2025 · 5 citations · Cited by this paper
  39. [Chinese multidisciplinary expert consensus on the rational use of surufatinib in clinical practice（2024 edition）]. · 2024 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)